IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Teva to Buy Merck KGaA’s Generics?

1:50 PM MDT | July 26, 2007 | Chemical Week Editorial Staff

Teva Pharmaceutical Industries (Petach Tikva, Israel) is likely to be selected to acquire Merck KGaA’s generic pharmaceutical business, sources say. Merck KGaA invited offers for the business but says it has not made a final decision to divest. Aggressive bidding had pushed the price of the generics business up to €4 billion-€5 billion ($5.5 billion-$6.8 billion) by the close of a revised round of bids on April 30, sources add. The other bidders are reportedly Mylan (Canonsburg, PA), and a joint offer by private equity firms Apax Partners and Bain...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa